# A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease

Study · id `cardio:ct-nct05432167` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05432167](<https://clinicaltrials.gov/study/NCT05432167>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05432167

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 195 participants.

## Technical summary

Registry record NCT05432167. Randomized; double masking; primary purpose treatment. Start 2022-04-29 (actual); primary completion 2024-05-02 (actual). Results posted on 2025-05-20.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 195 participants (enrolled count; ClinicalTrials.gov record NCT05432167, source copy `cardio:ctgov-nct05432167-2025-05-20`, retrieved 2026-10-26)
- Started: 2022-04-29 (actual) (ClinicalTrials.gov record NCT05432167, source copy `cardio:ctgov-nct05432167-2025-05-20`, retrieved 2026-10-26)
- Primary completion: 2024-05-02 (actual) (ClinicalTrials.gov record NCT05432167, source copy `cardio:ctgov-nct05432167-2025-05-20`, retrieved 2026-10-26)
- Completion: 2024-05-02 (actual) (ClinicalTrials.gov record NCT05432167, source copy `cardio:ctgov-nct05432167-2025-05-20`, retrieved 2026-10-26)
- Results first posted: 2025-05-20 (ClinicalTrials.gov record NCT05432167, source copy `cardio:ctgov-nct05432167-2025-05-20`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05432167, source copy `cardio:ctgov-nct05432167-2025-05-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05432167-2025-05-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease
- Condition: Uncontrolled Hypertension
- Condition: Chronic Kidney Diseases
- Intervention (Drug): CIN-107
- Intervention (Drug): Placebo
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY
- Collaborator: Parexel
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)
- Registry lists this organization as a collaborator: Parexel (`cardio:org-parexel`)

## Provenance

Content hash: cccdaf52c562a797887a269710bd315f22b638b66fcef1b871df0af47655a63a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
